J9210 Emapalumab Injection Reimbursement

HCPCS Level II code J9210 denotes the administration unit for emapalumab-lzsg, a targeted biologic delivered as an injectable therapy (1 mg per unit). This code captures dosing units for a specialty medication used in specific therapeutic indications and is relevant for billing outpatient infusion visits and clinic-based administration. Nationally, accurate coding for high-cost biologics like emapalumab-lzsg affects payer coverage determinations, claims processing, and specialty pharmacy workflows.

Key payers addressed in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of code definition and clinical context, typical places of service for administration, and what to expect in payer coverage and claim adjudication practices. The publication also highlights common billing considerations and related documentation elements needed to support medical necessity.

This report is intended to inform billing staff, revenue cycle leaders, and clinical program managers about the administrative and policy context surrounding HCPCS Level II code J9210, including national payer landscapes, coding precision importance, and areas where policy updates or payer guidelines commonly influence reimbursement and prior authorization workflows.

Billing Code Overview

HCPCS Level II code J9210 represents injection, emapalumab-lzsg, 1 mg, an injectable biologic therapy. The service type is therapeutic injection / infused biologic administration. The typical site of service is outpatient infusion or clinic-based injectable administration, including hospital outpatient departments, physician offices, and specialty infusion centers.

Data not available in the input.

Clinical Context

A patient with suspected or confirmed primary hemophagocytic lymphohistiocytosis (HLH) or macrophage activation syndrome (MAS) is evaluated in a tertiary care immunology or hematology clinic or inpatient ward. The treating team decides to initiate targeted cytokine therapy with J9210 (emapalumab-lzsg, 1 mg) due to persistent, severe hyperinflammation evidenced by high ferritin, cytopenias, fevers, elevated soluble IL-2 receptor (sCD25), and organ dysfunction despite initial immunosuppressive measures. The service is typically delivered in an outpatient infusion center, hospital outpatient department, or inpatient setting depending on acuity.

Workflow: the patient is assessed by a hematologist/immunologist; baseline labs (CBC, CMP, ferritin, triglycerides, fibrinogen, sCD25, infectious workup) are obtained. Medication is prepared by pharmacy and administered intravenously by infusion nursing. Vital signs and monitoring for infusion reactions and infection are performed during and after the infusion. Dosing and frequency follow specialty protocols; documentation includes indication, drug name and HCPCS code J9210, lot number, amount administered (mg), route, start/end times, and any modifiers applicable to the encounter.

Coding Specifications

Modifier	Description	When to Use
`00`	No modifier

Taxonomy Code	Specialty	Notes
`2080P0207X`	Hematology	Hematologists commonly manage HLH and prescribe `J9210`
`2080N0004X`	Allergy & Immunology	Specialists in immune dysregulation who initiate targeted cytokine therapies
`163W00000X`	Pediatric Hematology-Oncology	Pediatric specialists frequently treat HLH in children
`364S00000X`	Hospitalist	Hospitalists coordinate inpatient administration and monitoring
`335T00000X`	Infusion Nurse	Registered nurses who administer and monitor IV biologic therapies

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`D76.1`	Hemophagocytic lymphohistiocytosis (HLH)	Primary indication for emapalumab; targeted therapy for severe, refractory HLH
`D76.2`	Hemophagocytic syndrome due to underlying condition	Used when HLH is secondary to infection, malignancy, or autoimmune disease
`D76.8`	Other histiocytosis syndromes	Use when specific histiocytic disorder variants present with hyperinflammation
`M35.8`	Other specified systemic involvement of connective tissue	May be used for macrophage activation syndrome in systemic autoimmune disease
`R65.21`	Severe sepsis with septic shock	Sometimes present as differential or concurrent critical illness requiring careful evaluation before therapy
`T88.7XXA`	Unspecified adverse effect of drug, initial encounter	Used if prior therapy caused severe adverse reaction prompting switch to emapalumab

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`96413`	Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug	Commonly used to bill the infusion administration visit for a single-agent IV biologic infusion when appropriate
`96415`	Chemotherapy administration, each additional hour	Used if infusion or observation extends beyond the initial hour
`96365`	Intravenous infusion, therapeutic, prophylactic, or diagnostic; initial, up to 1 hour	Alternative for non-oncologic IV therapeutic infusions in outpatient settings
`96366`	Each additional hour (use with `96365`/`96367`)	Billed when infusion time exceeds the initial unit
`99070`	Supplies and equipment provided by the physician over and above those usually included with the service	Used for special infusion-related supplies not included in standard reimbursement

OpenPayer

Summary & Overview

HCPCS J9210: Emapalumab-lzsg Injection, 1 mg